Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis

Meta-analysis of 6 outcomes trials of 4 SGLT2 inhibitors suggest an associated reduction in risk of major adverse cardiovascular events (0.90; 95% CI, 0.85-0.95), hospitalization for heart failure /CV death (HR, 0.78; 0.73-0.84), and kidney outcomes (0.62; 0.56-0.70).

JAMA Cardiology